Recognising the prominent role of biosimilar medicines in delivering access to life-changing biological therapies, the ongoing dialogue on cancer and other non-communicable diseases is pointing towards greater value for healthcare systems, enabling progress towards integrated care for patients. Throughout the conference, debate and exchanges, as well as the presentation of examples and current practices, will foster ideas and data sharing.

The aim of this event is to multiply perspectives on existing challenges and future opportunities for biosimilar medicines policy to drive efficiency and contribute to the transformation of healthcare systems, and to inform the revision of the Pharmaceutical legislation.

Join us and have your say! As a participant in this event, you will:

• interact openly with thought leaders in the field
• engage in vibrant discussions with the full spectrum of healthcare stakeholders, policy makers and industry
• deepen your knowledge on the latest regulatory and scientific hot topics
• comprehend the impact that upcoming policy frameworks will have on access to standards of care and competition in the biologics market
• broaden your understanding of complex market access and procurement features
• factor in international developments when considering the longer-term perspective
• access actionable takeaways and good practices from experts in their fields with relevance to your daily work

We look forward to welcoming you to our event in Brussels!

In the meantime, please take a look at the April BIOS22 webinar "Biosimilar medicines: Changing patient pathways, Changing outcomes" during which we discussed biosimilar medicines value for healthcare.

• BIOS22 webinar
• Article "The availability of biosimilar medicines offers an equally effective, better value option for physicians and patients"

REGISTER NOW

CONTACT
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo. M: +39 345 21 777 22
For more information on the events click click here